These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8458176)

  • 1. Pharmacokinetics of oxaprozin.
    Hale VG; Bashaw ED
    Clin Pharm; 1993 Apr; 12(4):255-6. PubMed ID: 8458176
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetics of oxaprozin after multiple doses].
    Suwa T; Urano H; Tsuji A
    Yakugaku Zasshi; 1987 Jun; 107(6):440-8. PubMed ID: 3681662
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.
    Scavone JM; Ochs HR; Greenblatt DJ; Matlis R
    Eur J Clin Pharmacol; 1988; 35(1):105-8. PubMed ID: 3220091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panic disorder in a patient taking oxaprozin.
    Hough DW; Sellers R; Cantilena LR
    Am J Psychiatry; 1995 Jan; 152(1):149. PubMed ID: 7802107
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.
    Audet PR; Knowles JA; Troy SM; Walker BR; Morrison G
    Clin Pharmacol Ther; 1988 Sep; 44(3):303-9. PubMed ID: 3416552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay interaction between oxaprozin and phenytoin.
    Patel T; Radomski KM; Chandler MH
    Ann Pharmacother; 1997 Feb; 31(2):254. PubMed ID: 9034434
    [No Abstract]   [Full Text] [Related]  

  • 7. The transsynovial distribution of oxaprozin.
    Kurowski M; Thabe H
    Agents Actions; 1989 Jun; 27(3-4):458-60. PubMed ID: 2801338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of oxaprozin.
    Davies NM
    Clin Pharmacokinet; 1998 Dec; 35(6):425-36. PubMed ID: 9884815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
    Karim A
    J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.
    Lopes-de-Araújo J; Neves AR; Gouveia VM; Moura CC; Nunes C; Reis S
    Pharm Res; 2016 Feb; 33(2):301-14. PubMed ID: 26350105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaprozin: kinetic and dynamic profile in the treatment of pain.
    Kean WF
    Curr Med Res Opin; 2004 Aug; 20(8):1275-7. PubMed ID: 15324530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose.
    Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J
    J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro).
    Camara PD; Audette L; Velletri K; Breitenbecher P; Rosner M; Griffiths WC
    Clin Chem; 1995 Jan; 41(1):115-6. PubMed ID: 7813058
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of significant stereoselectivity in pharmacokinetics of tiaprofenic acid.
    Jamali F
    Eur J Clin Pharmacol; 1997; 52(3):243-6. PubMed ID: 9218935
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of sustained action tiaprofenic acid in elderly arthritic patients.
    Hosie GA; Hosie J
    Drugs; 1988; 35 Suppl 1():52. PubMed ID: 3359946
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of tiaprofenic acid in elderly multimorbid patients.
    Platt D; Eicher H; Rieck W; Hilgert D
    Drugs; 1988; 35 Suppl 1():53-6. PubMed ID: 3359947
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonlinear pharmacokinetics and protein binding of tiaprofenic acid in female Lewis rats.
    Benincosa LJ; Morris ME
    J Pharm Sci; 1993 Apr; 82(4):429-30. PubMed ID: 8468689
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological profile of oxaprozin eye drops.
    Bucolo C; Maltese A
    J Ocul Pharmacol Ther; 2002 Feb; 18(1):75-81. PubMed ID: 11858617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Todd PA; Brogden RN
    Drugs; 1986 Oct; 32(4):291-312. PubMed ID: 3536423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The analgesic and antipyretic effects of a non-steroidal anti-inflammatory drug, oxaprozin, in experimental animals].
    Amanuma F; Okuyama S; Orikasa S; Hashimoto S; Yamada C; Sakagawa T; Tsutsui Y; Tarumoto Y; Aihara H; Kameyama T
    Nihon Yakurigaku Zasshi; 1984 Apr; 83(4):345-54. PubMed ID: 6611288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.